- 4 Menu Items From the Past That McDonald's Should Bring Back
- 15 Cheap Cities Where You Don't Need a High Salary to Buy a House
- 20 Worst Cars of All Time
- U.S. Companies Find Cheap Labor -- and Growing Consumer Market -- in Philippines
- Tesla (TSLA) Stock Lower Today After Price Target Cut and Negative Analyst Note
The U.S. launch of Orexigen's obesity pill Contrave is outpacing the competition.
Activist hedge fund Sarissa Capital is starting a proxy fight to force the ouster of Ariad Pharmaceuticals founder and CEO Harvey Berger.
The maker of exoskeletons for paraplegics went public on the NASDAQ late last year, and though shares have tumbled, the CEO is confident in the company's growth.
Suitors are lining up too woo Salix Pharmaceuticals, and investors, anticipating a healthy purchase price, have pushed shares up more than 30% year-to-date.
Advaxis stock rallied after a private placement showed added fund participation. Read how this move has rebutted the short thesis.
Macrocure is picking up momentum after the wound care company's IPO struggled to get out of the gate last summer, said the company's CEO Nissim Mashiach.
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Achillion Pharmaceuticals announced a 10 million-share stock offering Tuesday night.
Which big pharmaceutical stocks should investors stay away from in 2015?
3D bioprinting technology sounds cool and actually works, but can it help Organovo make money?
Wall Street traded lower in midday trading Monday as the drama in Greece continues.
The letter of the day was 'A' as Abercrombie & Fitch, Alcoa and Apple all received analyst revisions on Monday.
Whether Regulus can still succeed with a multi-shot regimen or a combination requiring a shot and daily pills will depend on results from studies not yet conducted.
Keryx Biopharmaceuticals gave all 12 of the investment banks with research coverage of the company a slice of its $110 million stock offering.
Not all IPOs live up to their hype. In fact, some IPOs pop right out of the gate because of just that: hype.
Select the service that is right for you!COMPARE ALL SERVICES
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV